Proactive Investors - Run By Investors For Investors

Constellation Pharmaceuticals presents poster on studies involving drug therapy to treat bladder cancer

Patricia Keller, senior scientist at Constellation, made the poster presentation at the American Association for Cancer Research in Denver
bladder
The poster discusses results of Constellation’s work with its second-generation EZH2 inhibitor CPI-0209 in bladder cancer models

Constellation Pharmaceuticals Inc (NASDAQ:CNST) fell into the red Monday on the same day the company presented a poster on studies involving the company’s drug therapy to treat bladder cancer.

The Cambridge, Massachusetts-based company’s stock recently traded at $8.99 a share, down 15.4% on higher-than-average volume.

Patricia Keller, senior scientist at Constellation, made the poster presentation titled "targeting epigentic dysregulation in bladder cancer through inhibition of EZH2" at the Bladder Cancer: Transforming the Field meeting of the American Association for Cancer Research in Denver.

The poster discusses results of Constellation’s work with its second-generation EZH2 inhibitor CPI-0209 in bladder cancer models, exploring whether ARIDA mutation status affected responsiveness to CPI-0209 treatment, according to a statement. 

ARID1A, a protein that is a key component of the SWI/SNF chromatin remodeling complex, is mutated in about 25% of muscle-invasive bladder cancers, the company said.

Constellation used CPI-0209 in long-term phenotypic growth assays in a panel of 21 bladder cancer cell lines, demonstrating preferential treatment sensitivity that correlated with increased cell death in cell lines harboring ARID1A mutations. Transcriptional profiling after CPI-0209 treatment showed widespread activation of EZH2 target gene expression, the company said. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full CNST profile View Profile

Constellation Pharmaceuticals Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
man pointing to brain
April 25 2019
Brain Scientific’s EEG technology is far cheaper and less bulky than a traditional EEG system, but provides EEG tracings of the same quality
Sativa
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use